Cannabis use and opioid relapse

An exploratory survival analysis of prospectively collected data

Bibliographic Data

ID15518356
AuthorsLeen Naji (0000-0003-0994-1109, Impact, corresponding author), Tea Rosic (0000-0001-7406-4056, University of Ottawa), Nitika Sanger (0000-0002-5883-1873, McMaster University), Brittany B Dennis (0000-0002-3691-5400, McMaster University), Brittany Dennis (0000-0002-4909-9609), Alannah Hillmer (0000-0002-5535-7432, McMaster University), Jacqueline Hudson (McMaster University), Andrew Worster (0000-0001-7085-5061, McMaster University), James Paul (0000-0001-7367-5816, McMaster University), David C Marsh (0000-0002-8769-1785, Laurentian University), Lehana Thabane (0000-0003-0355-9734, McMaster University), Zainab Samaan (0000-0002-5974-9361, McMaster University)
Year2022
Volume13
Pages1046649-1046649
Publication date2022-11-16
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2022.1046649
PMID36465312
OpenAlexW4309314180
LanguageEN
References cited30

Our analysis failed to show cannabis to be protective against relapse to opioid use in patients receiving buprenorphine-naloxone for OUD. We identified that individuals who inject drugs, are on higher doses of buprenorphine-naloxone, or have been in treatment for less than two years have a higher hazard for relapse. The presence of such factors may thus warrant closer patient follow-up and more stringent treatment protocols to mitigate risk of relapse and potential overdose

Cannabis · Data science · Exploratory analysis · Opioid · Psychiatry · Cannabis and Cannabinoid Research · Medicine · Opioid Use Disorder Treatment · Psychology · Substance Abuse Treatment and Outcomes · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access